Went public 3/28/2000 at $18 apiece
Filing Range:5 mil. shares @ $17 to $19
Shares Outstanding:22.83 mil. shares
Prudential Vector Healthcare/U.S. Bancorp Piper Jaffray
(Data in $ millions)
Total Revenue – –
Net Loss -8.57 -20.9
Allos Therapeutics is a pharmaceutical company focused on developing and commercializing innovative small molecule drugs, initially for improving cancer treatments. The company’s lead candidate is RSR13, a synthetic small molecule that increases the release of oxygen from hemoglobin. In February 2000, management commenced Phase III clinical trials on RSR13 in combination with radiation therapy for the treatment of brain metastases, or tumors which have spread to the brain. In addition to improving existing treatments for cancer, the company believes RSR13 can be used to treat many other diseases and clincial conditions attributed to or aggravated by oxygen deprivation in the body, known as hypoxia. The company’s studies indicate that RSR13 effectively increases tumor oxygenation, thereby reducing the percentage of hypoxic cells within malignant tumors and enhancing the cytotoxic effect of radiation therapy. The beneficial effects of RSR13 are the result of causing increased amounts of oxygen release from blood flowing through the tumor. It is the oxygen, and not the drug, which diffuses across the cancer cell membranes to oxygenate the tumors. RSR13, which has been administered safely to more than 360 patients, has been found to significantly improve the efficacy of radiation therapy for treating brain metastases and glioblastoma multiforme, a highly aggressive form of primary brain cancer.
Estimated net proceeds of $82.7 million will be used for research and development ($50 mil.), including clinical trials, process development and manufacturing support, with the balance earmarked for general corporate purposes.
Oak Investment Partners, Sprout Group, Johnson & Johnson Development Corp., Marquette Venture Partners, International BM Biomedicine Holdings Inc., Schroder Ventures, INVESCO Private Capital Inc.